Utidelone
 | |
| Clinical data | |
|---|---|
| Trade names | 優替帝 |
| Other names | Epothilone D; desoxyepothilone B |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C27H41NO5S |
| Molar mass | 491.69 g·mol−1 |
Utidelone is a pharmaceutical drug for the treatment of metastatic breast cancer. It was approved for use in China in 2021.[1][2]
Utidelone is a member of the epothilone class of natural products, which are metabolites produced by the soil-dwelling myxobacterium Sorangium cellulosum.[3] It is also known as epothilone D.
References
[edit]- ^ "New Drug Approvals in China in 2021". diaglobal.org. 2 May 2022.
- ^ Villegas C, González-Chavarría I, Burgos V, Iturra-Beiza H, Ulrich H, Paz C (March 2023). "Epothilones as Natural Compounds for Novel Anticancer Drugs Development". International Journal of Molecular Sciences. 24 (7): 6063. doi:10.3390/ijms24076063. PMC 10093981. PMID 37047035.
- ^ Avendaño C, Menéndez JC (2023). "Anticancer drugs targeting tubulin and microtubules". Medicinal Chemistry of Anticancer Drugs: 445–491. doi:10.1016/B978-0-12-818549-0.00017-0. ISBN 978-0-12-818549-0.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |